A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.

Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of these patients responded. Nine patients received Cisplatinum and only one patient had a partial r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, A. S., Phillips, D. E., Cook, J. A., Helliwell, T. R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968228/
https://www.ncbi.nlm.nih.gov/pubmed/7678976
_version_ 1782134695292567552
author Jones, A. S.
Phillips, D. E.
Cook, J. A.
Helliwell, T. R.
author_facet Jones, A. S.
Phillips, D. E.
Cook, J. A.
Helliwell, T. R.
author_sort Jones, A. S.
collection PubMed
description Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of these patients responded. Nine patients received Cisplatinum and only one patient had a partial response. The trial suggests that chemotherapy has no place in the treatment of advanced salivary gland malignant tumours.
format Text
id pubmed-1968228
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19682282009-09-10 A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands. Jones, A. S. Phillips, D. E. Cook, J. A. Helliwell, T. R. Br J Cancer Research Article Sixteen patients with advanced and recurrent malignant salivary gland tumours were admitted to a randomised trial and the response assessed. Seven patients received Epirubicin/5-Fluorouracil and none of these patients responded. Nine patients received Cisplatinum and only one patient had a partial response. The trial suggests that chemotherapy has no place in the treatment of advanced salivary gland malignant tumours. Nature Publishing Group 1993-01 /pmc/articles/PMC1968228/ /pubmed/7678976 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Jones, A. S.
Phillips, D. E.
Cook, J. A.
Helliwell, T. R.
A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
title A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
title_full A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
title_fullStr A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
title_full_unstemmed A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
title_short A randomised phase II trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
title_sort randomised phase ii trial of epirubicin and 5-fluorouracil versus cisplatinum in the palliation of advanced and recurrent malignant tumour of the salivary glands.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968228/
https://www.ncbi.nlm.nih.gov/pubmed/7678976
work_keys_str_mv AT jonesas arandomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT phillipsde arandomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT cookja arandomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT helliwelltr arandomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT jonesas randomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT phillipsde randomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT cookja randomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands
AT helliwelltr randomisedphaseiitrialofepirubicinand5fluorouracilversuscisplatinuminthepalliationofadvancedandrecurrentmalignanttumourofthesalivaryglands

Ejemplares similares